Phase I clinical trial of epitope peptides based vaccines both targeting RNF43 and VEGFR2 in patients with advanced colorectal cancer.

Phase I clinical trial of epitope peptides based vaccines both targeting RNF43 and VEGFR2 in patients with advanced colorectal cancer. - Phase I clinical trial of epitope peptides based vaccines both targeting RNF43 and VEGFR2 in patients with advanced colorectal cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000956

Enrollment

Registered

2007-12-23

Start date

2007-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable colorectal cancer

Interventions

Vaccination using epitope peptide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Performance status 0-2 HLA-A24 No responce to CPT-11,5-FU, LV, Oxialiplatin) etc

Exclusion criteria

Exclusion criteria: pregnancy uncontroled infection uncontroled cerebral metastasis etc.

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026